Published in CA Cancer J Clin on March 11, 2005
Low-Cost Molecular Cervical Cancer Screening Study | NCT01231945
Laparoscopic Hepatectomy Versus Open Hepatectomy for PHC | NCT02014025
Acceptance of Human Papillomavirus Vaccination in Postpartum Women (HPV Acceptance) | NCT00730704
HIV and Other Risk Factors for Esophageal Squamous Cell Carcinoma in Malawi | NCT03160209
The Cxbladder Rule-out of Recurrent Urothelial Carcinoma | NCT03673202
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature (2008) 18.21
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat (2005) 11.27
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer (2006) 8.83
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol (2010) 6.53
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13
Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer (2005) 6.06
Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med (2013) 5.92
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90
Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol (2010) 5.87
Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case-control study. BMJ (2009) 5.79
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73
Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ (2009) 5.69
Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol (2009) 5.56
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology (2008) 5.53
Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg (2009) 5.38
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol (2008) 5.04
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Association between smoking and risk of bladder cancer among men and women. JAMA (2011) 4.31
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol (2011) 3.95
Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology (2009) 3.92
The global burden of cancer: priorities for prevention. Carcinogenesis (2009) 3.73
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res (2008) 3.70
Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol (2009) 3.67
Early detection of superficial squamous cell carcinoma in the head and neck region and esophagus by narrow band imaging: a multicenter randomized controlled trial. J Clin Oncol (2010) 3.64
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A (2009) 3.64
Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer (2010) 3.59
Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther (2006) 3.56
HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis (2007) 3.56
A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet (2010) 3.53
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene (2009) 3.51
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer (2009) 3.46
Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol (2008) 3.45
Predictive accuracy of the Liverpool Lung Project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. Ann Intern Med (2012) 3.45
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res (2009) 3.44
Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev (2010) 3.41
Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol (2006) 3.34
Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol (2008) 3.34
The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer (2011) 3.31
Cannabis use and risk of lung cancer: a case-control study. Eur Respir J (2008) 3.29
Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet (2010) 3.21
Primary prevention of colorectal cancer. Gastroenterology (2010) 3.20
DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest (2008) 3.17
Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer. Science (2008) 3.16
The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer (2007) 3.15
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol (2012) 3.08
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol (2008) 3.03
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med (2008) 3.02
Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther (2008) 2.96
The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis (2011) 2.96
Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol (2011) 2.96
STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest (2008) 2.95
Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet (2010) 2.95
Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis (2007) 2.93
Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet (2010) 2.92
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer (2008) 2.86
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol (2008) 2.85
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol (2009) 2.82
Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: pooled analyses of 424,519 participants. Lancet Oncol (2010) 2.81
Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res (2008) 2.81
Environmental causes of esophageal cancer. Gastroenterol Clin North Am (2009) 2.80
Development of a measurement tool to assess public awareness of cancer. Br J Cancer (2009) 2.79
Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA (2010) 2.78
A fresh look at oncology facts on south central Asia and SAARC countries. South Asian J Cancer (2012) 2.78
Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med (2011) 2.77
AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest (2006) 2.74
Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol (2014) 2.73
Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol (2008) 2.71
Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med (2013) 2.70
An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat (2007) 2.65
FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet (2009) 2.62
TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell (2012) 2.60
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol (2008) 2.59
Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst (2009) 2.57
Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One (2011) 2.57
Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A (2007) 2.56
miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer (2010) 2.51
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Health effects of light and intermittent smoking: a review. Circulation (2010) 2.46
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
The gut microbiome modulates colon tumorigenesis. MBio (2013) 2.45
Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol (2008) 2.44
Implementation of 'see-and-treat' cervical cancer prevention services linked to HIV care in Zambia. AIDS (2009) 2.42
Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol (2007) 2.40
Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology (2009) 2.39
Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol (2011) 2.37
Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer (2009) 2.33
Is breast cancer the same disease in Asian and Western countries? World J Surg (2010) 2.33
CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer (2009) 2.32
EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res (2011) 2.32
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014) 40.30
Estimating the world cancer burden: Globocan 2000. Int J Cancer (2001) 16.92
Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat (2005) 11.27
Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol (2012) 9.28
Genetic pathways to glioblastoma: a population-based study. Cancer Res (2004) 8.87
Global cancer statistics. CA Cancer J Clin (1999) 8.82
Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer (1999) 8.61
International variation in prostate cancer incidence and mortality rates. Eur Urol (2012) 8.04
Chapter 2: The burden of HPV-related cancers. Vaccine (2006) 7.70
Cancer incidence and mortality in Europe, 2004. Ann Oncol (2005) 6.47
Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer (1993) 6.24
Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer (1999) 6.11
Worldwide burden of cervical cancer in 2008. Ann Oncol (2011) 5.66
Global burden of human papillomavirus and related diseases. Vaccine (2012) 5.48
Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer (2008) 5.00
Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet (2012) 4.76
Cancer mortality in India: a nationally representative survey. Lancet (2012) 4.30
Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer (2002) 4.02
International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer (2005) 3.81
Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness. Eur J Cancer (2009) 3.67
Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer (2002) 3.17
Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol (2005) 3.16
Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer (1993) 3.13
Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol (2013) 3.00
Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer (1997) 2.65
Epidemiology of biliary tract cancers: an update. Ann Oncol (2008) 2.51
Cancer burden in Africa and opportunities for prevention. Cancer (2012) 2.51
NORDCAN--a Nordic tool for cancer information, planning, quality control and research. Acta Oncol (2010) 2.48
Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev (1997) 2.36
Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res (1999) 2.24
National comparisons of lung cancer survival in England, Norway and Sweden 2001-2004: differences occur early in follow-up. Thorax (2010) 2.21
Gastric cancer in Japan--honing treatment, seeking causes. N Engl J Med (2008) 2.18
Fifty years of cancer incidence: CI5 I-IX. Int J Cancer (2010) 2.14
Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer (2010) 2.13
Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer (2009) 2.12
Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst (2007) 2.08
International trends in the incidence of malignant melanoma 1953-2008--are recent generations at higher or lower risk? Int J Cancer (2012) 2.07
Effect of ambient solar ultraviolet radiation on incidence of squamous-cell carcinoma of the eye. Lancet (1996) 1.81
Trends in cancer incidence in Chennai city (1982-2006) and statewide predictions of future burden in Tamil Nadu (2007-16). Natl Med J India (2011) 1.81
Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer (2009) 1.80
High incidence of nasopharyngeal carcinoma in native people of Sarawak, Borneo Island. Cancer Epidemiol Biomarkers Prev (2004) 1.74
Breast cancer survival in England, Norway and Sweden: a population-based comparison. Int J Cancer (2010) 1.74
A population-based comparison of the survival of patients with colorectal cancer in England, Norway and Sweden between 1996 and 2004. Gut (2011) 1.70
ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res (2003) 1.64
Occupation and larynx and hypopharynx cancer: a job-exposure matrix approach in an international case-control study in France, Italy, Spain and Switzerland. Cancer Causes Control (2003) 1.59
Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer (2013) 1.57
The epidemiology of non-Hodgkin's lymphoma: comparison of nodal and extra-nodal sites. Int J Cancer (1997) 1.57
Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. Int J Cancer (2002) 1.51
Cancer deaths in India: is the model-based approach valid? Bull World Health Organ (1994) 1.46
Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. Ann Oncol (2008) 1.38
Survival of patients diagnosed with cancer in the Nordic countries up to 1999-2003 followed to the end of 2006. A critical overview of the results. Acta Oncol (2010) 1.36
Clinical relevance of conditional survival of cancer patients in europe: age-specific analyses of 13 cancers. J Clin Oncol (2010) 1.34
Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes Control (2003) 1.32
The cure of cancer: a European perspective. Eur J Cancer (2009) 1.31
Colorectal cancer survival in socioeconomic groups in England: variation is mainly in the short term after diagnosis. Eur J Cancer (2011) 1.27
Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. Ann Oncol (2008) 1.25
Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol (2010) 1.23
Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol (2007) 1.22
Trends in the survival of patients diagnosed with breast cancer in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol (2010) 1.16
Lung cancer in Europe in 2000: epidemiology, prevention, and early detection. Lancet Oncol (2003) 1.15
Trends in survival of patients diagnosed with cancer of the digestive organs in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol (2010) 1.15
Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004. Ann Oncol (2007) 1.12
The burden of stomach cancer in indigenous populations: a systematic review and global assessment. Gut (2013) 1.11
Cancer incidence and mortality in France in 1975-95. Eur J Cancer Prev (1997) 1.10
Cancer in the African population of Harare, Zimbabwe, 1990-1992. Int J Cancer (1995) 1.08
Increase in breast cancer incidence among older women in Mumbai: 30-year trends and predictions to 2025. Cancer Epidemiol (2012) 1.08
The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies. PLoS One (2011) 1.08
Cancer Incidence in Five Continents. Age-specific and standardized incidence rates. IARC Sci Publ (1992) 1.07
Cancer incidence in Thailand, 1988-1991. Cancer Epidemiol Biomarkers Prev (1995) 1.05
Breast and cervical cancer in 187 countries between 1980 and 2010. Lancet (2012) 1.03
Trends in cervical cancer incidence and mortality in the Baltic countries, Bulgaria and Romania. Int J Cancer (2011) 1.03
Time trends in pharyngeal cancer incidence in Norway 1981-2005: a subsite analysis based on a reabstraction and recoding of registered cases. Cancer Causes Control (2010) 1.02
Quantifying differences in breast cancer survival between England and Norway. Cancer Epidemiol (2011) 1.02
Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe. Eur J Cancer (2006) 1.02
Occupation and larynx and hypopharynx cancer: an international case-control study in France, Italy, Spain, and Switzerland. Cancer Causes Control (2003) 1.01
Trends in colorectal cancer incidence in Norway 1962-2006: an interpretation of the temporal patterns by anatomic subsite. Int J Cancer (2010) 1.00
Trends in the survival of patients diagnosed with kidney or urinary bladder cancer in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol (2010) 0.99
Endometrial cancer incidence trends in Norway during 1953-2007 and predictions for 2008-2027. Int J Cancer (2010) 0.98
Age-period-cohort analysis of primary bone cancer incidence rates in the United States (1976-2005). Cancer Epidemiol Biomarkers Prev (2011) 0.97
Trends in the survival of patients diagnosed with malignant neoplasms of lymphoid, haematopoietic, and related tissue in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol (2010) 0.97
Declining rates of hepatocellular carcinoma in urban Shanghai: incidence trends in 1976-2005. Eur J Epidemiol (2011) 0.96
Trends in the survival of patients diagnosed with malignant melanoma of the skin in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol (2010) 0.96
Cancer incidence and mortality patterns in South Eastern Europe in the last decade: gaps persist compared with the rest of Europe. Eur J Cancer (2012) 0.96
Marriage and parenthood among childhood cancer survivors: a report from the Italian AIEOP Off-Therapy Registry. Haematologica (2011) 0.95
Increasing mortality rates of common malignancies in Colombia: an emerging problem. Cancer (2004) 0.94
The role of parents, friends and teachers in adolescents' cigarette smoking and tombak dipping in Sudan. Tob Control (2010) 0.94
Risk of primary non-breast cancer after female breast cancer by age at diagnosis. Cancer Epidemiol Biomarkers Prev (2011) 0.94
Patterns and trends in cancer mortality in Colombia 1984-2008. Cancer Epidemiol (2013) 0.93
Subsite-specific dietary risk factors for colorectal cancer: a review of cohort studies. J Oncol (2013) 0.92
The XRCC1 -77T->C variant: haplotypes, breast cancer risk, response to radiotherapy and the cellular response to DNA damage. Carcinogenesis (2006) 0.92
Frailty modeling of the bimodal age-incidence of Hodgkin lymphoma in the Nordic countries. Cancer Epidemiol Biomarkers Prev (2011) 0.92
Estimating and validating disability-adjusted life years at the global level: a methodological framework for cancer. BMC Med Res Methodol (2012) 0.92
Ensuring quality in studies linking cancer registries and biobanks. Acta Oncol (2010) 0.91
Lung cancer mortality patterns in selected Central, Eastern and Southern European countries. Int J Cancer (2004) 0.91
CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among Asian populations. Cancer Epidemiol Biomarkers Prev (2008) 0.91
Trends in the overall survival of cancer patients diagnosed 1964-2003 in the Nordic countries followed up to the end of 2006: the importance of case-mix. Acta Oncol (2010) 0.90
A comparison of two methods to estimate the cancer incidence and mortality burden in China in 2005. Asian Pac J Cancer Prev (2010) 0.90